02204nas a2200217   4500000000100000008004100001260004400042653001700086653002900103653001000132653003400142100002200176700002400198700002200222700001500244700001500259245009700274856013200371520146900503022001401972       2025                            d  bSpringer Science and Business Media LLC10aCase reports10ainfectious skin diseases10aLepra10aLepromatous leprosy diagnosis1 aArenas Sanchez KA1 aCaicedo Vásquez PG1 aSandoval Calle LM1 aHuertas JF1 aVinueza JM00aLucio’s Phenomenon in Hansen’s Disease: A Case Report of a Condition Not to Be Forgotten  uhttps://www.cureus.com/articles/315788-lucios-phenomenon-in-hansens-disease-a-case-report-of-a-condition-not-to-be-forgotten#!/3 a<p>Leprosy is a chronic infectious and granulomatous disease that occurs predominantly in tropical regions, primarily affecting the skin, mucous membranes, and peripheral nervous system. It is caused by&nbsp;<em>Mycobacterium leprae</em>&nbsp;and&nbsp;<em>Mycobacterium lepromatosis</em>. It is characterized by hypopigmented lesions, sensory disturbances, absence of hair in the affected area, and anhidrosis, although some of these manifestations may not be initially present. Leprosy remains a public health challenge due to its wide spectrum of clinical manifestations and leprosy-related reactions. It is a potentially curable disease, especially since the introduction of multidrug therapy (MDT) as the standard treatment, provided that diagnosis and treatment are initiated early. Lucio’s phenomenon is a rare leprosy reaction characterized by extensive necrotic skin lesions and multisystem involvement, with a high rate of morbidity and mortality. Its treatment remains challenging. Currently, the recommended therapy includes the initiation of MDT-comprising dapsone, clofazimine, and rifampicin-combined with systemic corticosteroids and specialized wound care. In cases of secondary bacterial infection, the use of antibiotics is advised based on local epidemiological data. We present the case of a patient with Lucio’s phenomenon who was treated with combined MDT and systemic corticosteroids, resulting in significant clinical improvement.</p>
  a2168-8184